Tags

Type your tag names separated by a space and hit enter

Treatment of hirsutism related to micropolycystic ovary syndrome (MPCO) with two low-dose oestrogen oral contraceptives: a comparative randomized evaluation.
Acta Eur Fertil. 1990 May-Jun; 21(3):139-41.AE

Abstract

In order to evaluate the clinical and endocrinological efficacy of two low-dose oral contraceptives (OC) containing 30 micrograms Ethinylestradiol (EE) and 150 micrograms Desogestrel (DG) and 75 micrograms Gestodene (GD), respectively, an open randomized study was carried out in 34 young hirsute women, matched for body mass index and age. All of them met endocrine and ultrasonic criteria for Micropolycystic Ovary Syndrome (MPCO). The participants were randomly assigned to one of two pill groups (each of 17). The serum values for Total Testosterone (TT), Free Testosterone (FT), Androstenedione (A), Dehydroepiandrosterone (DHEA), Dehydroepiandrosterone Sulphate (DHEAS), 17-Hydroxyprogesterone (17Pg), Sex Hormone Binding Globulin (SHBG), Ceruloplasmin (CP), as well as Ferriman-Gallwey Index (FGI) and Free Androgen Index (FAI) were evaluated prior to and after EE-DG and EE-GD 6 cycle treatment. A significant decrease in TT, FT, A, 17Pg, DHEA, DHEAS, FGI, FAI was observed, SHRG and CP increased significantly. There were no significant differences between the two OC. Our results seem to indicate that both OC are equipotent as far as their pharmacological profile and residual androgenic activity are concerned. Therefore, these OC may represent a highly effective and suitable alternative to the treatment of hyperandrogenism related to MPCO.

Authors+Show Affiliations

Sobbrio GA
Instit. of Clinica Medica I, University of Messina, School of Medicine, Italy.
Granata A
No affiliation info available
D'Arrigo F
No affiliation info available
Arena D
No affiliation info available
Panacea A
No affiliation info available
Trimarchi F
No affiliation info available
Granese D
No affiliation info available
Pullè C
No affiliation info available

MeSH

17-alpha-HydroxyprogesteroneAdolescentAdultAndrostenedioneCeruloplasminContraceptives, Oral, HormonalDehydroepiandrosteroneDehydroepiandrosterone SulfateDesogestrelEthinyl EstradiolFemaleHirsutismHumansHydroxyprogesteronesNorpregnenesPolycystic Ovary SyndromeSex Hormone-Binding GlobulinTestosterone

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

2149912

Citation

Sobbrio, G A., et al. "Treatment of Hirsutism Related to Micropolycystic Ovary Syndrome (MPCO) With Two Low-dose Oestrogen Oral Contraceptives: a Comparative Randomized Evaluation." Acta Europaea Fertilitatis, vol. 21, no. 3, 1990, pp. 139-41.
Sobbrio GA, Granata A, D'Arrigo F, et al. Treatment of hirsutism related to micropolycystic ovary syndrome (MPCO) with two low-dose oestrogen oral contraceptives: a comparative randomized evaluation. Acta Eur Fertil. 1990;21(3):139-41.
Sobbrio, G. A., Granata, A., D'Arrigo, F., Arena, D., Panacea, A., Trimarchi, F., Granese, D., & Pullè, C. (1990). Treatment of hirsutism related to micropolycystic ovary syndrome (MPCO) with two low-dose oestrogen oral contraceptives: a comparative randomized evaluation. Acta Europaea Fertilitatis, 21(3), 139-41.
Sobbrio GA, et al. Treatment of Hirsutism Related to Micropolycystic Ovary Syndrome (MPCO) With Two Low-dose Oestrogen Oral Contraceptives: a Comparative Randomized Evaluation. Acta Eur Fertil. 1990 May-Jun;21(3):139-41. PubMed PMID: 2149912.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment of hirsutism related to micropolycystic ovary syndrome (MPCO) with two low-dose oestrogen oral contraceptives: a comparative randomized evaluation. AU - Sobbrio,G A, AU - Granata,A, AU - D'Arrigo,F, AU - Arena,D, AU - Panacea,A, AU - Trimarchi,F, AU - Granese,D, AU - Pullè,C, PY - 1990/5/1/pubmed PY - 1990/5/1/medline PY - 1990/5/1/entrez KW - Androgens KW - Biology KW - Clinical Research KW - Comparative Studies KW - Contraception KW - Contraceptive Agents, Estrogen--therapeutic use KW - Contraceptive Agents, Female--therapeutic use KW - Contraceptive Agents, Progestin--therapeutic use KW - Contraceptive Agents--therapeutic use KW - Contraceptive Methods--therapeutic use KW - Dehydroepiandrosterone--analysis KW - Desogestrel--therapeutic use KW - Developed Countries KW - Diseases KW - Endocrine System KW - Ethinyl Estradiol--therapeutic use KW - Europe KW - Examinations And Diagnoses KW - Family Planning KW - Gestodene--therapeutic use KW - Hirsutism KW - Hormones KW - Italy KW - Laboratory Examinations And Diagnoses KW - Mediterranean Countries KW - Oral Contraceptives, Low-dose--therapeutic use KW - Oral Contraceptives--therapeutic use KW - Physiology KW - Prospective Studies KW - Research Methodology KW - Signs And Symptoms KW - Southern Europe KW - Studies KW - Testosterone--analysis KW - Treatment SP - 139 EP - 41 JF - Acta Europaea fertilitatis JO - Acta Eur Fertil VL - 21 IS - 3 N2 - In order to evaluate the clinical and endocrinological efficacy of two low-dose oral contraceptives (OC) containing 30 micrograms Ethinylestradiol (EE) and 150 micrograms Desogestrel (DG) and 75 micrograms Gestodene (GD), respectively, an open randomized study was carried out in 34 young hirsute women, matched for body mass index and age. All of them met endocrine and ultrasonic criteria for Micropolycystic Ovary Syndrome (MPCO). The participants were randomly assigned to one of two pill groups (each of 17). The serum values for Total Testosterone (TT), Free Testosterone (FT), Androstenedione (A), Dehydroepiandrosterone (DHEA), Dehydroepiandrosterone Sulphate (DHEAS), 17-Hydroxyprogesterone (17Pg), Sex Hormone Binding Globulin (SHBG), Ceruloplasmin (CP), as well as Ferriman-Gallwey Index (FGI) and Free Androgen Index (FAI) were evaluated prior to and after EE-DG and EE-GD 6 cycle treatment. A significant decrease in TT, FT, A, 17Pg, DHEA, DHEAS, FGI, FAI was observed, SHRG and CP increased significantly. There were no significant differences between the two OC. Our results seem to indicate that both OC are equipotent as far as their pharmacological profile and residual androgenic activity are concerned. Therefore, these OC may represent a highly effective and suitable alternative to the treatment of hyperandrogenism related to MPCO. SN - 0587-2421 UR - https://www.unboundmedicine.com/medline/citation/2149912/Treatment_of_hirsutism_related_to_micropolycystic_ovary_syndrome__MPCO__with_two_low_dose_oestrogen_oral_contraceptives:_a_comparative_randomized_evaluation_ DB - PRIME DP - Unbound Medicine ER -